Beximco looks beyond Bangladesh with $6.6 sofosbuvir
This article was originally published in Scrip
Bangladesh's Beximco Pharmaceuticals may not be the first onto the local market with its cut-price version of Gilead's hepatitis C blockbuster Sovaldi (sofosbuvir), but the company appears to be pulling out all the stops to establish a stronghold in the market.
You may also be interested in...
Bangladesh's HCV market report card currently reads along these lines: generic versions of Sovaldi and Daklinza have made significant gains leaving interferon by the wayside, while generic Harvoni has had a quiet run. But, the arrival of cut-price Epclusa generics could bring change, besides putting the spotlight on the growing prowess of the South Asian nation's pharmaceutical industry.
Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.